胸腺五肽对晚期非小细胞肺癌化学治疗后免疫功能的影响

Influence of thymopentin on immunologic function in advanced-stage patients with nonsmall-cell lung cancer

目的观察胸腺五肽对晚期非小细胞肺癌(NSCLC)化学治疗患者免疫功能的影响。方法64例晚期NSCLC患者随机分为常规治疗组和胸腺五肽治疗组,常规治疗组采用NP方案(长春瑞滨+顺铂)治疗;胸腺五肽治疗组在NP方案基础上加用胸腺五肽1 mg溶于2 mL注射用水中,肌肉注射,每日1次,连用4周;完成2周期化学治疗后比较2组血T细胞亚群和血清免疫球蛋白IgG、IgA、IgM的变化,并与正常对照组进行比较。结果常规治疗组和胸腺五肽组之间治疗前CD3+、CD4+、CD8+、CD4+/CD8+均无显著差异(P>0.05),均与正常对照组有明显差异(P<0.01)。胸腺五肽组治疗后CD3+、CD4+、CD8+与治疗前比较有极显著差异(P<0.01),CD4+/CD8+与治疗前比较有显著差异(P<0.05);治疗后胸腺五肽组与常规治疗组比较CD4+、CD8+、CD4+/CD8+均有显著差异(P<0.01);治疗前后常规治疗组和胸腺五肽组IgA、IgM、IgG均无显著差异(P>0.05)。结论晚期NSCLC患者免疫功能低下,胸腺五肽可提高晚期非小细胞肺癌患者的细胞免疫功能。

Objective To observed the efficacy of thymopentin based on chemotherapy on immunologic function in patients with non-small cell lung cancer（NSCLC） in their advanced stage. Methods Sixty-four patients of NSCLC were divided randomly into routine therapy group and thymopentin therapy group. The routine therapy group were only given NP regimen （ vinorelbine plus cisplatin） , the thymopentin therapy group, based on NP regimen, were given 1 mg thymopentin intramuscular in- jection by dissolving in 2 ml of water, once daily, successively for four weeks. After two cycles, changes of T-lymphocyte subset and serum IgG, IgA and IgM of two groups were compared, and also compared with those of the control group. Results Before chemotherapy, no visible change in CD3 ^＋ , CD4 ^＋ , CD8 ^＋ and the ratio of CD4 ^＋/CD8 ^＋ was found in two groups（ P 〉 0.05 ） ,significantly difference appeared,compared with the control group（ P 〈0.01 ）. After the chemotherapy, CD3 ^＋ , CD4 ^＋ and CD8 ^＋ of the thymopentin therapy group was significantly different from those before the chemotherapy （ P 〈 0.05 ） ; the ratio of CD4 ^＋ / CD8 ^＋ of thymopentin therapy group was also significantly different（ P 〈 0.01 ） ; CD4^＋ , CD8 ^＋ , CD4^＋/CD8^＋ of thymopentin therapy group was significantly different compared with routine therapy（ P 〈 0.01 ）. No visible change of two groups in IgA, IgM, IgG was found in the NSCLC patients before and after chemotherapy. Conclusion The immunologic function is suppressed in the NLCSC patients in their advanced stage,thymopentin may enhanced cellular immunologic functions of the NLCSC patients in their advanced stage.